Immunohistochemical Evaluation of Necrotic Malignant Melanomas
|
|
- Erik Carr
- 7 years ago
- Views:
Transcription
1 Anatomic Pathology / EVALUATION OF NECROTIC MALIGNANT MELANOMAS Immunohistochemical Evaluation of Necrotic Malignant Melanomas Daisuke Nonaka, MD, Jordan Laser, MD, Rachel Tucker, HTL(ASCP), and Jonathan Melamed, MD Key Words: Malignant melanoma; Necrosis; HMB-45; Melan-A; Tyrosinase; PNL2; S-100 protein; Microphthalmia transcription factor; MITF DOI: /WKEN4ER9GXJ9GG31 Abstract We evaluated 35 cases of malignant melanomas with substantial necrosis immunostained with S-100, HMB-45, Melan-A, tyrosinase, PNL2, and microphthalmia transcription factor (MITF). Staining patterns were evaluated in viable and necrotic areas of the tumors. S-100 was the most sensitive marker (97%) in the viable tumors, but necrotic areas demonstrated nonspecific staining. Viable tumors stained variably for HMB-45 (25 [71%]), Melan-A (28 [80%]), tyrosinase (30 [86%]), and PNL2 (23 [66%]). Necrotic areas focally reacted to the same antibodies. The necrotic areas that retained immunoreactivity for these markers corresponded to areas where the outline of the tumor cells could still be recognized as ghost cells on the H&E-stained section. Areas that showed complete coagulative necrosis were negative for melanoma markers. MITF variably stained in the viable tumors but was completely negative in necrotic areas. Our study demonstrated that a combination of antibodies to HMB-45, tyrosinase, and PNL2 detected melanocytic differentiation in necrotic areas in 80% of cases. In diagnostic surgical pathology, it is not uncommon to see a tumor with extensive or even complete necrosis. Among common malignant neoplasms, malignant melanoma is notorious for its capability of metastasizing to any organs and sites and mimicking various types of benign and malignant neoplasms, and the history of cutaneous melanocytic lesions is not always evident in metastatic melanoma cases. In addition, it is not unusual for a metastatic melanoma to manifest as a completely necrotic mass. Thus, malignant melanoma is always a consideration in the differential diagnosis for tumors with extensive necrosis. A few immunohistochemical markers such as cytokeratins, particularly AE1/AE3, and thyroglobulin have been reported as useful in identifying the lineage of necrotic tumors. 1,2 The usefulness of immunohistochemical study for the diagnosis of necrotic melanoma has not been extensively investigated. 2,3 Therefore, we evaluated the diagnostic usefulness of 6 immunohistochemical markers of melanocytic differentiation by applying them to 35 melanoma specimens with extensive necrosis. Materials and Methods We retrieved 35 cases of primary (2 cases) and metastatic (33 cases) malignant melanomas with substantial necrosis, ie, the necrotic component comprising more than half of the entire tumor, from our archives. All the cases showed extensive necrosis adjacent to the viable tumor. The following 6 immunohistochemical stains were performed: S-100 protein (polyclonal, dilution 1:12,000; DAKO, Carpinteria, CA; no epitope retrieval), HMB-45 (HMB-45, Am J Clin Pathol 2007;127: DOI: /WKEN4ER9GXJ9GG31 787
2 Nonaka et al / EVALUATION OF NECROTIC MALIGNANT MELANOMAS dilution 1:50; DAKO; heat-induced epitope retrieval [HIER] in citrate buffer), Melan-A (A103, dilution 1:400; Novocastra, Newcastle upon Tyne, England; HIER in citrate buffer), tyrosinase (T311, dilution 1:200; Novocastra; HIER in EDTA buffer), PNL2 (PNL2, dilution 1:50; DAKO; HIER in DakoCytomation target retrieval solution), and microphthalmia transcription factor (MITF; D5, dilution 1:100; DAKO; HIER in citrate buffer). Ten cases of various extensively necrotic lesions were also stained with HMB-45, Melan-A, tyrosinase, and PNL2. Those lesions include 4 cases of high-grade sarcoma (leiomyosarcoma, gastrointestinal stromal tumor, and undifferentiated pleomorphic sarcoma), 2 cases of cutaneous squamous cell carcinoma, 1 case each of adrenocortical carcinoma, ovarian serous papillary carcinoma, and pulmonary adenocarcinoma, and 1 case of abscess. For 10 selected cases of necrotic melanoma, cytokeratin AE1/AE3 (dilution 1:20; Zymed, San Francisco, CA; protease digestion), CD31 (JC70A, dilution 1:600, DAKO; HIER in citrate buffer), CD45 (2B11 + PD7/26, dilution 1:250; DAKO; HIER in citrate buffer), CD68 (KP1, dilution 1:500; DAKO; HIER in citrate buffer), chromogranin A (LK2H10, dilution 1:50; Novocastra; HIER in citrate buffer), and smooth muscle actin (SMA; 1A4, dilution 1:400; DAKO; HIER in citrate buffer) were also performed. Staining patterns were evaluated in viable and necrotic areas of the tumors. Results Immunohistochemical Results on Viable Tumor S-100 protein was the most sensitive marker (34/35 [97%]) in the viable tumors, as expected, and was positive in all cases except 1 case, with a positive ratio ranging from 5% to 100%. The S-100 protein negative case was positive for the other 5 markers in the viable areas. Viable tumors stained variably for HMB-45 (25/35 [71%]), Melan-A (28/35 [80%]), tyrosinase (30/35 [86%]), PNL2 (23/35 [66%]), and MITF (24/35 [69%]) Table 1. Two cases (6%) were completely negative for all 5 markers, whereas 17 cases (49%) were positive for all 5 markers. Three cases expressed only tyrosinase. Two cases expressed 2 markers, ie, tyrosinase and Melan-A. Six cases expressed 3 of 5 markers: tyrosinase, Melan-A, and MITF in 3 cases; tyrosinase, HMB-45, and PNL2 in 1 case; Melan-A, HMB-45, and PNL2 in 1 case; and HMB-45, PNL2, and MITF in 1 case. Five cases expressed 4 of 5 markers, with no reaction to one of the following markers: HMB-45 in 1 case, PNL2 in 2 cases, and MITF in 3 cases. The viable tumors were completely negative for AE1/AE3, CD31, CD45, CD68, chromogranin, and SMA. In addition, viable portions of all 10 cases of extensively necrotic nonmelanocytic lesions were completely negative for HMB-45, Melan-A, tyrosinase, and PNL2. Immunohistochemical Results on Necrotic Tumor Of the cases, 17 (49%) demonstrated diffuse but weak nonspecific staining for S-100 protein in the necrotic areas Image 1B. Necrotic components also stained for HMB-45 (23/35 [66%]) Image 1C, Melan-A (20/35 [57%]), tyrosinase (23/35 [66%]) Image 1D, and PNL2 (19/35 [54%]). The intensity and distribution of staining were weak and focal compared with the viable areas. MITF showed a completely negative reaction in necrotic areas Image 1E. Individual tumors expressed the same immunohistochemical markers in the viable and necrotic areas, with the exception of MITF, which was negative in the necrotic areas of all 35 specimens. Generally, the necrotic areas that reacted to the melanoma markers corresponded to areas where the outline of the tumor cells could still be recognized as ghost cells on the H&E-stained section Image 1A. Areas that showed complete coagulative necrosis were negative for the melanoma markers except for occasional nonspecific staining with S-100 protein. A combination of 3 markers, HMB-45, tyrosinase, and PNL2 or HMB-45, tyrosinase, and Melan-A, could detect melanocytic differentiation in the necrotic areas of 80% (n = 28) and 77% (n = 27) of cases, respectively. A combination of the 2 common markers, HMB-45 and Melan-A, could detect melanocytic differentiation in 74% of cases (n = 26). The necrotic areas were completely negative for AE1/AE3, CD31, chromogranin, and SMA. The CD45 reaction was predominantly present at borders between the viable and necrotic areas, and the positive cells were morphologically consistent with infiltrating lymphocytes. Of 10 Table 1 Immunohistochemical Results in 35 Malignant Melanomas * S-100 HMB-45 Melan-A Tyrosinase PNL2 MITF Viable area Necrotic area MITF, microphthalmia transcription factor. * Data are given as number of positive cases. 788 Am J Clin Pathol 2007;127: DOI: /WKEN4ER9GXJ9GG31
3 Anatomic Pathology / ORIGINAL ARTICLE A B C D E Image 1 A, Melanoma with coagulative necrosis containing ghost cells, so-called ongoing necrosis (H&E, 20). B, S-100 protein often demonstrates diffuse, nonspecific staining in the necrotic area of the tumor ( 20). C, HMB-45 focally stains in the ongoing necrotic area of the tumor ( 20). D, Tyrosinase focally stains in the ongoing necrotic area of the tumor ( 20). E, Microphthalmia transcription factor is negative in both ongoing and complete necrotic areas of the tumor ( 20). Am J Clin Pathol 2007;127: DOI: /WKEN4ER9GXJ9GG31
4 Nonaka et al / EVALUATION OF NECROTIC MALIGNANT MELANOMAS cases, 5 demonstrated a weak CD45 reaction in the necrotic tumor cells immediately adjacent to the CD45+ infiltrating lymphocytes. A similar finding was also observed with CD68 staining, which highlighted the infiltrating macrophage population and, in addition, the surrounding necrotic tumor cells at a weaker intensity in 3 of 10 cases. The necrotic portions of all 10 cases of extensively necrotic nonmelanocytic lesions were completely negative for HMB-45, Melan-A, tyrosinase, and PNL2. Discussion Extensively or completely necrotic tumors can be diagnostically challenging. This situation may be encountered in a surgical resection specimen for malignant neoplasm, a lymph node biopsy for malignant lymphoma or metastatic malignant neoplasm, or a small biopsy specimen from the necrotic part of the tumor. The potential situations that could cause such necrosis are as follows: (1) adjuvant therapy before removal of the tumor 4 ; (2) a rapidly growing tumor that is susceptible to tumor apoptosis and necrosis; (3) certain tumors, particularly oncocytic neoplasms represented by Hürthle cell neoplasm of the thyroid, with a known propensity for spontaneous infarct or infarct induced by procedures such as fine-needle aspiration (FNA); and (4) FNA performed as an initial diagnostic modality; various studies have reported histomorphologic alterations including sclerosis, vascular and spindle cell proliferation, and partial to complete infarction or necrosis. 3 It is also known that melanoma cells can undergo self-destruction via programmed cell death, ie, apoptosis, regulated by multiple molecules that exert proapoptotic or antiapoptotic effects. The former include p53, Bax, tumor necrosis factor, and tumor necrosis factor related apoptosisinducing ligand, whereas the latter include bcl-2, bcl-x L, Mcl-1, and survivin. 5 A few studies have evaluated the usefulness of immunohistochemical staining in identifying the lineage of necrotic tumors. A study by Judkins et al 2 found high sensitivity and specificity in cytokeratin antibodies such as AE1, AE1/AE3, S903, and PANCK. Of 2 cases of malignant lymphoma, both retained CD45 (leukocyte common antigen), but this marker was also expressed in 3 of 14 cases of necrotic carcinoma. S- 100 protein was positive in 1 of 2 cases of malignant melanoma, but 1 of 14 cases of carcinoma was also positive for this marker. Judkins et al 1 reported the usefulness of cytokeratins such as AE1/AE3 in thyroid tumors with spontaneous or post-fna necrosis, including papillary carcinomas, Hürthle cell neoplasms, and follicular adenomas. Thyroglobulin was also reported to be expressed by papillary carcinomas and Hürthle cell neoplasms but not follicular adenomas. S-100 protein immunoreactivity was identified only in viable areas of some Hürthle cell neoplasms and papillary carcinoma but not in necrotic components. Nasuti et al 3 described 3 cases of lymphadenopathy for which FNA was performed. After diagnoses of metastatic squamous cell carcinoma for 2 cases and metastatic malignant melanoma for 1 case were made, lymph node dissection was performed in each case, which showed only coagulative necrosis with ghost cells and no viable tumor. However, immunostains for cytokeratin (AE1/AE3) and melanoma markers (HMB45, Melan-A, and S-100 protein) confirmed the diagnoses of metastatic squamous cell carcinoma and metastatic melanoma, despite extensive necrosis. Generally, expressions of HMB-45, Melan-A, and tyrosinase in metastatic melanomas are weaker in intensity and patchier in distribution than those in primary melanoma, as our study showed. It has been reported that metastatic melanomas subsequent to multiple primary melanomas or multiple recurrent melanomas significantly lose expression of the melanoma common tumor antigens such as Melan-A. 6 It has been postulated that tumor antigens can be recognized by cell-mediated immunity during development of the primary cancer by the formation of antigen-specific cytotoxic lymphocytes and that such recognition leads to the destruction of the tumor cells expressing the antigen (tumor regression); tumor cells with antigen loss then have a selective survival advantage accounting for the subsequent predominance of neoplastic cells with antigen loss. 6 The areas of necrotic tumor that reacted to the melanoma markers were located between the viable tumors and areas of the complete coagulative necrosis, and the necrotic tumor cells could still be recognized as ghost cells. These ghost cells were characterized by cytoplasmic eosinophilia, variable preservation of nuclear chromatin, and obscured cytoplasmic borders. These cells have been described as necrobiosis or ongoing necrosis. 4 The study on these ghost cells in hepatocellular carcinomas treated by radiofrequency ablation demonstrated that antibody to detect single-strand DNA labeled the nuclei in the ghost cells but not in the viable or completely necrotic cells, whereas mitochondrial antibody labeled the cytoplasm of viable cells but not cells of ongoing or complete necrosis. Necrotic areas of melanomas were negative for nonmelanocytic markers such as AE1/AE3, CD31, CD45, CD68, chromogranin A, and SMA, whereas extensively necrotic nonmelanocytic lesions were negative for melanocytic markers such as HMB-45, Melan-A, tyrosinase, and PNL2. Both results support the sensitivity and specificity of HMB-45, Melan-A, tyrosinase, and PNL2 in the diagnosis of necrotic melanoma. Given that many metastatic melanomas immunohistochemically demonstrate variable immunoreactivity to melanoma 790 Am J Clin Pathol 2007;127: DOI: /WKEN4ER9GXJ9GG31
5 Anatomic Pathology / ORIGINAL ARTICLE markers, a panel of markers is recommended for the diagnosis of metastatic melanoma with extensive necrosis. Our study demonstrated that a combination of 3 markers, HMB-45, tyrosinase, and PNL2 or HMB-45, tyrosinase, and Melan-A, could detect melanocytic differentiation in the necrotic areas of 80% and 77% of cases, respectively. A combination of the 2 common markers, HMB-45 and Melan-A, could detect melanocytic differentiation in 74% of cases. S-100 protein and MITF are not reliable markers in this context; the former has a tendency for nonspecific staining, and the latter lacks sensitivity in necrotic areas. From the Department of Pathology, New York University Medical Center, New York, NY. Address correspondence to Dr Nonaka: Dept of Pathology, New York University Medical Center, TCH-461, 560 First Ave, New York, NY References 1. Judkins AR, Roberts SA, LiVolsi VA. Utility of immunohistochemistry in the evaluation of necrotic thyroid tumors. Hum Pathol. 1999;30: Judkins AR, Montone KT, LiVolsi VA, et al. Sensitivity and specificity of antibodies on necrotic tumor tissue. Am J Clin Pathol. 1998;110: Nasuti JF, Gupta PK, Baloch ZW. Clinical implications and value of immunohistochemical staining in the evaluation of lymph node infarction after fine-needle aspiration. Diagn Cytopathol. 2001;25: Itoh T, Orba Y, Takei H, et al. Immunohistochemical detection of hepatocellular carcinoma in the setting of ongoing necrosis after radiofrequency ablation. Mod Pathol. 2002;15: Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol. 2003;199: Saleh FH, Crotty KA, Hersey P, et al. Autonomous histopathological regression of primary tumours associated with specific immune responses to cancer antigens. J Pathol. 2003;200: Am J Clin Pathol 2007;127: DOI: /WKEN4ER9GXJ9GG31 791
The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin
Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,
More informationPNL2 MELANOCYTIC MARKER IN IMMUNOHISTOCHEMICAL EVALUATION OF PRIMARY MUCOSAL MELANOMA OF THE HEAD AND NECK
ORIGINAL ARTICLE PNL2 MELANOCYTIC MARKER IN IMMUNOHISTOCHEMICAL EVALUATION OF PRIMARY MUCOSAL MELANOMA OF THE HEAD AND NECK Luc G. Morris, MD, 1 Yong Hannah Wen, MD, PhD, 2 Daisuke Nonaka, MD, 2 Mark D.
More informationUpdate on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
More informationImmunohistochemical differentiation of metastatic tumours
Immunohistochemical differentiation of metastatic tumours Dr Abi Wheal ST1. TERA 3/2/14 Key points from a review article written by Daisuke Nonaka Intro Metastatic disease is the initial presentation in
More informationImmunohistochemistry of soft tissue tumors
Immunohistochemistry of soft tissue tumors Immunohistochemistry Major advances : antigen retrieval techniques (HIER) sensitive detection systems numerous antibodies of good quality Standardization : automated
More informationPractical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
More informationPATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma
More information20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC.
Utility of WT-1, p63, MOC31, Mesothelin, and Cytokeratin (K903 and CK5/6) Immunostains in Differentiating Adenocarcinoma, Squamous Cell Carcinoma, and Malignant Mesothelioma in Effusions Robert T. Pu,
More informationDiagnosis of Mesothelioma Pitfalls and Practical Information
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com
More informationOutline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
More informationThe develpemental origin of mesothelium
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal
More informationSeattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
More informationOvarian tumors Ancillary methods
Ovarian tumors Ancillary methods Ovarian tumor course Oslo, 24-25/11/14 Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway Division of
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationLYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons
LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:
More informationDiagnostic Challenge. Department of Pathology,
Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital
More informationAcadémie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-Bron
More informationATLAS OF HEAD AND NECK PATHOLOGY THYROID PAPILLARY CARCINOMA
Papillary carcinoma is the most common of thyroid malignancies and occurs in all age groups but particularly in women under 45 years of age. There is a high rate of cervical metastatic disease and yet
More informationCytopathology Case Presentation #8
Cytopathology Case Presentation #8 Emily E. Volk, MD William Beaumont Hospital, Troy, MI Jonathan H. Hughes, MD Laboratory Medicine Consultants, Las Vegas, Nevada Clinical History 44 year old woman presents
More informationValidation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach
Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach Kerry C. Councilman, MD Assistant Professor University of Colorado Denver Goals: BRAF Mutation
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationDisclosures. Learning Objectives. Effusion = Confusion. Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell!
Disclosures Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! No Relevant Financial Relationships with Commercial Interests Syed Z. Ali, M.D. Syed Z. Ali, M.D. Associate Professor of
More informationYOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
More informationImmunohistochemistry on cytology specimens from pleural and peritoneal fluid
Immunohistochemistry on cytology specimens from pleural and peritoneal fluid Dr Naveena Singh Consultant Pathologist Bart health NHS Trust London United Kingdom Disclosures and Acknowledgements I have
More informationHow To Test For Cancer
Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell! Effusion = Confusion Syed Z. Ali, M.D. Professor of Pathology and Radiology The Johns Hopkins Hospital Baltimore, Maryland Diagnostic
More informationHKCPath Anatomical Pathology Peer Review and Scores : PDF version for download
AP2003R1 http://hkcpath.org. Correspondence: pkhui@ha.org.hk 1of 10 07/08/2003 HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP141 Bone Marrow: Metastatic Carcinoma from
More informationRenal Tumors with Eosinophilic Cytoplasm: 2013 Classification. Jesse K. McKenney, MD Associate Head, Surgical Pathology
Renal Tumors with Eosinophilic Cytoplasm: 2013 Classification Jesse K. McKenney, MD Associate Head, Surgical Pathology Renal Epithelial Neoplasia History 1981: WHO Classification of Renal Neoplasms 1.
More informationSomething Old, Something New.
Something Old, Something New. Michelle A. Fajardo, D.O. Loma Linda University Medical Center Clinical Presentation 6 year old boy, presented with hematuria Renal mass demonstrated by ultrasound & CT scan
More informationIntroduction: Tumor Swelling / new growth / mass. Two types of growth disorders: Non-Neoplastic. Secondary / adaptation due to other cause.
Disorders of Growth Introduction: Tumor Swelling / new growth / mass Two types of growth disorders: Non-Neoplastic Secondary / adaptation due to other cause. Neoplastic. Primary growth abnormality. Non-Neoplastic
More informationThe evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS
The evolving pathology of solitary fibrous tumours Luciane Dreher Irion MREH / CMFT / NSOPS Historical review Haemangiopericytoma (HPC) first described primarily as a soft tissue vascular tumour of pericytic
More informationBRIEF REPORTS. Introduction
BRIEF REPORTS WT1, Monoclonal CEA, TTF1, and CA125 Antibodies in the Differential Diagnosis of Lung, Breast, and Ovarian Adenocarcinomas in Serous Effusions Weijian Zhu, M.D., Ph.D. and Claire W. Michael,
More informationArticles. Nordic Immunohistochemical Quality Control (NordiQC) - An Organization for External Quality Assurance. Mogens Vyberg, MD
Articles Nordic Immunohistochemical Quality Control (NordiQC) - An Organization for External Quality Assurance Mogens Vyberg, MD Institute of Pathology. Aalborg Hospital Aarhus University Hospital Denmark
More informationCase of the. Month October, 2012
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix
More informationCorporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid
Corporate Medical Policy Molecular Markers in Fine Needle Aspirates of the Thyroid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_markers_in_fine_needle_aspirates_of_the_thyroid
More informationCytology of Lymph Nodes
Indications Cytology of Lymph Nodes Lymph node enlargement That was easy Mary Anna Thrall Don Meuten Indications Lymph node enlargement Suspect metastasis Normal sized lymph nodes are Normal Do NOT aspirate
More informationCASE OF THE MONTH AUGUST-2015 DR. GURUDUTT GUPTA HEAD HISTOPATHOLOGY
CASE OF THE MONTH AUGUST-2015 DR. GURUDUTT GUPTA HEAD HISTOPATHOLOGY CASE HISTORY 52Y MALE RIGHT RADICAL NEPHERECTOMY Case of right renal mass with IVC thrombus. History of surgery and RT for right occipital
More informationThe Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.
Where does Molecular Analysis of FNA Specimens fit into the evaluation of thyroid nodules? The Role of Genetic Testing in the Evaluation of Thyroid Nodules Ultrasound TSH Risk factors Jill E. Langer, MD
More informationhttp://www.springer.com/3-540-22006-2
http://www.springer.com/3-540-22006-2 1 Molecular Pathology Laboratory of the Future Christopher A. Moskaluk 1.1 The Past The integration of laboratory analysis with human medicine has traditionally been
More informationBRAF in the diagnostic evaluation of thyroid nodules
Symposium 13 Molecular markers in thyroid cancer: current role in clinical practice BRAF in the diagnostic evaluation of thyroid nodules Laura Fugazzola University of Milan, Italy Papillary carcinoma BRAF
More informationMETASTATIC CLEAR CELL RENAL CELL CARCINOMA TO THE SUBCUTANEOUS AREA IN ILLIAC FOSSA AND ADRENAL GLAND WITHOUT AN IDENTIFIABLE PRIMARY TUMOR
Indian J.Sci.Res. 5(1) : 121-125, 2014 METASTATIC CLEAR CELL RENAL CELL CARCINOMA TO THE SUBCUTANEOUS AREA IN ILLIAC FOSSA AND ADRENAL GLAND WITHOUT AN IDENTIFIABLE PRIMARY TUMOR a1 b c d REETA DHAR, SHILPI
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationIndex. F Factor VIII-related antigen, see VWF FactorXIIIa, for dermatofibroma, 272-275 5-HT, see Serotonin
A Acantholytic squamous cell carcinoma vs epithelioid angiosarcoma, 56-57 Acinic cell carcinoma of pancreas, 76-77 vs ductal adenocarcinoma, 74-75 vs islet cell tumor, 78-81 Adenomatoid tumor vs hemangioma,
More informationEfficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach
Efficient Tumor Immunohistochemistry A Differential Diagnosis-Driven Approach Publishing Team Erik Tanck (production manager/designer) Joshua Weikersheimer (publisher) Copyright 2006 by the American Society
More informationRenal Cell Carcinoma Associated with Xp11.2 Translocation: Clinicopathologic and Immunohistochemical Findings of 4 Cases
The Korean Journal of Pathology 2005; 39: 406-11 Renal Cell Carcinoma Associated with Xp11.2 Translocation: Clinicopathologic and Immunohistochemical Findings of 4 Cases Sanghui Park Ji-Eun Kwon Yeon-Lim
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationAtypical uterine leiomyoma: a case report and review of the literature
Manxhuka-Kerliu et al. Journal of Medical Case Reports (2016) 10:22 DOI 10.1186/s13256-016-0800-3 CASE REPORT Open Access Atypical uterine leiomyoma: a case report and review of the literature Suzana Manxhuka-Kerliu
More informationInformation Model Requirements of Post-Coordinated SNOMED CT Expressions for Structured Pathology Reports
Information Model Requirements of Post-Coordinated SNOMED CT Expressions for Structured Pathology Reports W. Scott Campbell, Ph.D., MBA James R. Campbell, MD Acknowledgements Steven H. Hinrichs, MD Chairman
More informationThe Diagnosis of Cancer in the Pathology Laboratory
The Diagnosis of Cancer in the Pathology Laboratory Dr Edward Sheffield Christmas Select 74 Meeting, Queen s Hotel Cheltenham, 3 rd December 2014 Agenda Overview of the pathology of cancer How specimens
More informationHistopathology of Colorectal Cancer after Neoadjuvant Chemoradiation Therapy
The Open Pathology Journal, 2009, 3, 91-98 91 Open Access Histopathology of Colorectal Cancer after Neoadjuvant Chemoradiation Therapy Maura O Neil * and Ivan Damjanov Department of Pathology and Laboratory
More informationWORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14
WORKPLACE SAFETY AND INSURANCE APPEALS TRIBUNAL DECISION NO. 1557/14 BEFORE: M. Crystal: Vice-Chair HEARING: August 20, 2014 at Toronto Written DATE OF DECISION: December 4, 2014 NEUTRAL CITATION: 2014
More informationA 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which
More informationTranslocation Renal Cell Carcinomas
Translocation Renal Cell Carcinomas Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Kidney cancer is not a single disease Clear cell (75%)
More informationBone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital
Bone Marrow Evaluation for Lymphoma Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital Indications One of the most common indications for a bone marrow biopsy is to evaluate for malignant lymphoma.
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More information- Slide Seminar - Endocrine pathology in non-endocrine organs. Case 11. Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa
- Slide Seminar - Endocrine pathology in non-endocrine organs Case 11 Stefano La Rosa, Gioacchino D Ambrosio, Fausto Sessa Dept. of Pathology, Multimedica, Milan, Italy Dept. of Surgical and Morphological
More informationFrozen Section Diagnosis
Frozen Section Diagnosis Dr Catherine M Corbishley Honorary Consultant Histopathologist St George s Healthcare NHS Trust and lead examiner final FRCPath Practical 2008-2011 Frozen Section Diagnosis The
More informationTitle: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma
Author's response to reviews Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma Authors: Tanner L Bartholow (bartholow.tanner@medstudent.pitt.edu) Uma R Chandran (chandranur@msx.upmc.edu)
More informationRENAL CELL CARCINOMA EPIDEMIOLOGY
RENAL CELL CARCINOMA: THE 2012 ISUP VANCOUVER CLASSIFICATION David Grignon MD, Indiana University, Indianapolis, IN RENAL CELL CARCINOMA EPIDEMIOLOGY Siegel et al. CaA Cancer J Clin 63:11-30, 2013 1 EPITHELIAL
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationCytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium
Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium Introduction 3 cavities with the same embryologic origin the mesoderme Pleura Exudates Pleura Peritoneum Pericardium 22%
More informationPRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT
PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT Dott. Francesco Pontieri (*) U.O. di Anatomia Patologica P.O. di Rossano (CS) Dott. Gian Franco Zannoni Anatomia Patologica Facoltà di Medicina e Chirurgia
More informationMEDICAL POLICY SUBJECT: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID EFFECTIVE DATE: 11/19/15
MEDICAL POLICY SUBJECT: MOLECULAR MARKERS IN FINE NEEDLE PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationClassificazione anatomo-patologica nei RCC Matteo Brunelli. Department of Pathology and Diagnostic, University di Verona, Italy
Classificazione anatomo-patologica nei RCC Matteo Brunelli Department of Pathology and Diagnostic, University di Verona, Italy WHO 2004 AFIP 2004 = ISUP Vancouver Classification 2013 5 newentities 3 emerging
More informationEmerging Subtypes in Renal Cancer. Donna E. Hansel, MD PhD Professor of Pathology, UC San Diego Division Chief, Anatomic Pathology dhansel@ucsd.
Emerging Subtypes in Renal Cancer Donna E. Hansel, MD PhD Professor of Pathology, UC San Diego Division Chief, Anatomic Pathology dhansel@ucsd.edu Some General Comments Fuhrman nuclear grading clear cell
More informationNew Concepts and Refinements to. Existing WHO (2004) Renal Cell. Tumor Categories In Adults
New Concepts and Refinements to Existing WHO (2004) Renal Cell Tumor Categories In Adults Dr Varsha Manucha Assistant Professor Department of Pathology and Laboratory Medicine Temple University Hospital
More informationPediatric Oncology for Otolaryngologists
Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department
More informationMAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER
Renal tumours WHO 4 MAJOR PARADIGM SHIFT IN EARLY 1990S IN UNDERSTANDING RENAL CANCER Molecular differential pathology of renal cell tumours G. KOVACS A CLASSIFICATION BASED ON UNDERSTANDING THE GENETIC
More informationCarcinosarcoma of the Ovary
Carcinosarcoma of the Ovary A Rare Finding Presented By: Kathryn Kiely Anisa I. Kanbour School of Cytotechnology of the University of Pittsburgh Medical Center Pittsburgh, PA Patient History 55 year old
More informationProblem Cases in Surgical Pathology XXV Congreso de la Sociedad Española de Patologia (SEAP) - Zaragoza, Mayo 18-21, 2011.
Problem Cases in Surgical Pathology XXV Congreso de la Sociedad Española de Patologia (SEAP) - Zaragoza, Mayo 18-21, 2011. Saul Suster, M.D. Medical College of Wisconsin Milwaukee, WI, USA Case - 2 Clinical
More informationLessons from a consultation practice
Pitfalls in the Application of Immunohistochemistry in Diagnostic Pathology Lessons from a consultation practice Kevin O. Leslie, MD Professor and Consultant Mayo Clinic Arizona Scottsdale, Arizona Presenter
More informationUpdate on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery
Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David
More informationEpithelial Tumors of the Kidney Diagnostic Problems and Recently Described Entities
Pathology of Renal Neoplasia Epithelial Tumors of the Kidney Diagnostic Problems and Recently Described Entities Wael A Sakr, MD Wayne State University School of Medicine CURRENT CLASSIFICATION = EPITHELIAL
More informationGladwyn Leiman, MCCCh, FIAC, FRCPath Scott Anderson, MD
Cytology Works shop #5 Gladwyn Leiman, MCCCh, FIAC, FRCPath Scott Anderson, MD Disclosur re information The speakers have no relationship that represents a possible conflict of interest with respect to
More informationClassificazioni citologiche: verso uno schema internazionale unificato?
Cytology and molecular biology for thyroid nodules diagnos6c categories to clinical ac6ons From Classificazioni citologiche: verso uno schema internazionale unificato? A. Crescenzi Diagnostic categories
More informationNeoplasia gastrica cistica: GIST o leiomiosarcoma? Sebastiano Cacciaguerra U. O. Chirurgia Pediatrica Ospedale Garibaldi Catania
Neoplasia gastrica cistica: GIST o leiomiosarcoma? Sebastiano Cacciaguerra U. O. Chirurgia Pediatrica Ospedale Garibaldi Neoplasia gastrica cistica: GIST o leiomiosarcoma? Aims of presentation Atypical
More informationPathology of lung cancer
Pathology of lung cancer EASO COURSE ON LUNG CANCER AND MESOTHELIOMA DAMASCUS (SYRIA), MAY 3-4, 2007 Gérard ABADJIAN MD Pathologist Associate Professor, Saint Joseph University Pathology Dept. Hôtel-Dieu
More informationThe Use of Immunohistochemistry to Distinguish Reactive Mesothelial Cells From Malignant Mesothelioma in Cytologic Effusions
The Use of Immunohistochemistry to Distinguish Reactive Mesothelial Cells From Malignant Mesothelioma in Cytologic Effusions Farnaz Hasteh, MD 1 ; Grace Y. Lin, MD, PhD 1 ; Noel Weidner, MD 1 ; and Claire
More informationEffusions: Mesothelioma and Metastatic Cancers
Effusions: Mesothelioma and Metastatic Cancers Malignant Mesothelioma Incidence: 2,500 cases/year ~60-80% pts with pleural MM relationship with asbestos exposure Other risk factors: radiation, other carcinogens,
More informationNeoplasms of the LUNG and PLEURA
Neoplasms of the LUNG and PLEURA 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 Case 1 Case Vignette HISTORY:
More informationLymphohistiocytoid Mesothelioma An Often Misdiagnosed Variant of Sarcomatoid Malignant Mesothelioma
Anatomic Pathology / LYMPHOHISTIOCYTOID MESOTHELIOMA Lymphohistiocytoid Mesothelioma An Often Misdiagnosed Variant of Sarcomatoid Malignant Mesothelioma Hasan S. Khalidi, MD, 1 L. Jeffrey Medeiros, MD,
More informationCHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.
Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs
More informationTUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD
TUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD Victor E. Reuter, MD Memorial Sloan-Kettering Cancer Center reuterv@mskcc.org 66 th Annual Pathology Seminar California Society of Pathologists Short
More informationINFLAMMATION AND REACTIVE CHANGES IN CERVICAL EPITHELIUM
INFLAMMATION AND REACTIVE CHANGES IN CERVICAL EPITHELIUM Inflammation is a response of a tissue to injury, often caused by invading microorganisms. The suffix which indicates inflammation is "-itis" (the
More information330 Diagnostic Cytopathology, Vol 34, No 5 # 2006 WILEY-LISS, INC.
Does Hurthle Cell Lesion/Neoplasm Predict Malignancy More Than Follicular Lesion/Neoplasm on Thyroid Fine-Needle Aspiration? Robert T. Pu, M.D., Ph.D., 1 * Jack Yang, M.D., 2 Patricia G. Wasserman, M.D.,
More informationTHE PATHOLOGY OF MEDIASTINAL MASSES. Anatomic Distribution of Mediastinal Masses
Page 1 of 5 THE PATHOLOGY OF MEDIASTINAL MASSES Dr. S. Boag 549-6666 Ext. 4190, mailto:%20boag@cliff.path.queensu.ca 1. INTRODUCTION A wide range of process, neoplastic and non-neoplastic, can produce
More informationTHYROID CANCER. I. Introduction
THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in
More informationHow To Test For Cancer With A Blood Test
Histolab Products AB Eva Alströmer Jonas Falgén Helsingborg 7-8/10 2010 Table 1 Formalin Fixation Times and Estrogen Receptor Staining With 25 Minutes Antigen Retrieval Pretreatment Formalin Q-Score Difference
More informationLung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology
Lung Carcinomas New 2015 WHO Classification Spasenija Savic Pathology ***EXPECTED SPRING 2015*** This authoritative, concise reference book provides an international standard for oncologists and pathologists
More informationWriting Group for the AACE Thyroid Scientific Committee. Bernet V, Hupart KH, Parangi S and Woeber KA
Molecular Diagnostic Testing of Thyroid Nodules with Indeterminate Cytopathology Summary Highlights Writing Group for the AACE Thyroid Scientific Committee Bernet V, Hupart KH, Parangi S and Woeber KA
More informationNovocastra Liquid Mouse Monoclonal Antibody CD141 (Thrombomodulin)
Novocastra Liquid Mouse Monoclonal Antibody CD141 (Thrombomodulin) Product Code: NCL-L-CD141 Leica Biosystems Newcastle Ltd Balliol Business Park West Benton Lane Newcastle Upon Tyne NE12 8EW United Kingdom
More informationHow to report Upper GI EMR/ESD specimens
Section of Pathology and Tumour Biology How to report Upper GI EMR/ESD specimens Dr.H.Grabsch Warning. Most of the criteria, methodologies, evidence presented in this talk are based on studies in early
More informationA PATIENT S GUIDE TO ABLATION THERAPY
A PATIENT S GUIDE TO ABLATION THERAPY THE DIVISION OF VASCULAR/INTERVENTIONAL RADIOLOGY THE ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL Treatment options for patients with cancer continue to expand, providing
More informationMalcolm Mattes, MD Ajay Tejwani, MD, MPH New York Methodist Hospital
Malcolm Mattes, MD Ajay Tejwani, MD, MPH New York Methodist Hospital 39 year old female patient who felt a mass in the right gluteal area. Slowly growing over the course of 2 3 months. The mass is associated
More informationRenal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD
Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD Department of Pathology University of Szeged, Hungary ISUP Vancouver Classification of Renal Neoplasia Am J Surg Pathol 37:14691489, 2013 13 histologic
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationD. FREQUENTLY ASKED QUESTIONS
ACR BI-RADS ATLAS D. FREQUENTLY ASKED QUESTIONS 1. Under MQSA, is it necessary to include a numeric assessment code (i.e., 0, 1, 2, 3, 4, 5, or 6) in addition to the assessment category in all mammography
More informationTumour Markers. What are Tumour Markers? How Are Tumour Markers Used?
Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or
More information